Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...

Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly the problem ...

Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...

The health reset that began in India after COVID-19 is no longer just about avoiding illness. It has quietly evolved into ...

For decades, cancer patients have been told that shrinking tumors meant accepting brutal side effects as the price of ...

Today, new-generation cancer drugs have significantly improved both effectiveness and safety, especially targeted therapies.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.

Often times, it takes the perspective of a youngster to realize something is amiss. For example, look at the beautiful ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.comMarket Intelligence Brief – The market is repricing risk around a single variable: detection. The most dangerous threats ...

Adderall, Ritalin and other stimulants prescribed for attention-deficit/hyperactivity disorder seem to work on brain areas ...